Efficacy of Epoetin Beta on Hemoglobin, Quality of Life, and Transfusion Needs in Patients with Anemia Due to Hormone-refractory Prostate Cancer - A Randomized Study

References

• Ornstein DK, Beiser JA, Andriole GL. Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999; 83: 43–6.
   Google Scholar
• Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997; 79: 933–41.
   PubMedGoogle Scholar
• Miller CB, Jones RJ, Piantadosi S, Aberhoff MD, Spivak JL. Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 1990; 322: 1689–92.
   Google Scholar
• Langer CJ. Anemia, fatigue and quality of life in advanced malignancy: potential therapeutic role for epoetin. Erythropoiesis-new dimensions in the treat-ment of anemia 1997; 8: 63–73.
   Google Scholar
• Esper P, Hampton JN, Smith DC, Pienta KJ. Quality of life evaluation in patients receiving treatment for advanced prostate cancer. Oncol Nurs Forum 1999; 26: 107–12.
   PubMedGoogle Scholar
• Abets RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (rHuEPO) for the treatment of anaemia of cancer. AlphaMed Press; 1991.
   Google Scholar
• Gamucci T, Thorel MF, Frasca AM, Giannarell D, Calabresi F. Erythropoietin for the prevention of anemia in neoplastic patients treated with cisplatin. Eur J Cancer 1993; 29A (Suppl 2): S13–14.
   Google Scholar
• Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, et at. Prediction of response to recombinant human erythropoietin (rHEpo) in anemia of malignancy. Haematologica 1996; 81: 434–41.
   Google Scholar
• Glimelius B, Linné T, Hoffman K, Larsson L, Svensson JH, Nasman P, et at. Epoetin beta in the treatment of anaemia in patients with advanced gastrointestinal cancer. J Clin Oncol 1998; 16: 434–40.
   Google Scholar
• Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anaemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994; 73: 2535–42.
   PubMed Web of Science ®Google Scholar
• Beshara S, Letocha H, Linde T, Wikstrom B, Sandhagen B, Nilsson S, et at. Anemia associated with advanced prostate, adenocarcinoma: effects of recombinant human erythropoietin. Prostate 1997; 31(3): 151–60.
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et at. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
   Google Scholar
• Bergman B, Sullivan M, Sorenson S. Quality of life during chemotherapy for small cell lung cancer. Acta Oncol 1992; 31: 19–28.
   Google Scholar
• Curran D, Fossa S, Aaronson N, Kiebert G, Kueppens F, Hall R, et at. Baseline quality of life of patients with advanced prostate cancer. Eur J Cancer 1997; 33: 1809–14.
   PubMedGoogle Scholar
• Sommers S, Ramsey SD. A review of quality of life evaluations in prostate cancer. Pharmaeconomics 1999; 16: 127–40.
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Fayers PM, Bjordal K. Health-related quality of life in Norwegian population assessed by the European Organisation for Research and Treatment of Cancer core quality of life questionnaire: the QLQ-C30 (+3). J Clin Oncol 1998; 16: 1188–96.
   Google Scholar
• Michelson H, Bolund C, Nilsson B, Brandberg Y. Health related quality of life measured by the EORTC QOL-C30-reference values from a large sample of the Swedish population. Acta Oncol 2000; 99: 477–84.
   Google Scholar
• Abets RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (rHuEPO) for the treatment of anaemia of cancer. Oncologist 1996; 1(3): 140–50.
   PubMedGoogle Scholar
• Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998; 16: 3412–25.
   Google Scholar
• Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchek-mydyian S, Vadhan-Raj S for the Procrit Study Group. Impact of therapy with epoetin-alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218–34.
   Google Scholar
• Ludwig H, Sundal E, Pechersdorfer M, Leitgeb C, Bauernhofer T, Beinhaurer A, et at. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemo-therapy. Cancer 1995; 76: 2319–29.
   Google Scholar
• Esper P, Redman BG. Supportive care, pain manage-ment, and quality of life in advanced prostate cancer. Urol Clin North Am 1999; 26: 375–89.
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in quality-of-life scores. J Clin Oncol 1998; 16: 139–44.
   Google Scholar
• King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996; 5: 555–67.
   PubMed Web of Science ®Google Scholar
• Sheffield RE, Sullivan SD, Salitiel E and Hishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy induced anemia. Ann Pharmacotherapy 1997; 31: 15–22.
   Google Scholar
• Cremieux P-Y, Finkelstein S, Berndt E, Crawford J, Stavin M. Cost effectiveness, quality adjusted life years and supportive care. Recombinant human erythropoietin as a treatment of cancer associated anemia. Pharmcoe-conomics 1999; 16: 459–72.
   Google Scholar